Compare Gitlab Inc (GTLB) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Gitlab Inc trades at $54.37 (market cap $8.92B), while Vertex Pharmaceuticals Incorporated trades at $514 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 14.3× Gitlab Inc's market cap, and Gitlab Inc is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| GTLB | VRTX | |
|---|---|---|
Market Cap | $8.92B | $127.55B |
Volume | 4,716,893 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $53.56 | $557.96 |
52-Week Low | $19.42 | $407.37 |
Typical Hold Time | 62 Days | 120 Days |
Enterprise Value | $7.66B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $51.99, up 0.7% on the day and near its 52-week high, supported by a bullish technical outlook and strong Q2 2026 earnings beats. Revenue growth accelerated to 21.3% year-over-year, with the company raising full-year guidance amid robust AI-driven demand for its DevSecOps platform. However, the stock trades at a high P/E ratio of 521.22, reflecting premium valuation despite negative net income margins.
The investment case hinges on GitLab's execution in monetizing AI and enterprise expansion, but risks include sustained profitability challenges and competitive pressure. Analysts are mixed with a Hold consensus, yet recent news highlights sales momentum and institutional interest, suggesting potential upside if growth targets are met.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
